Integral Announces Timothy Nobles as Chief Product Officer
SAN FRANCISCO--(BUSINESS WIRE)--Jun 3, 2025--
Integral, the only end-to-end regulated insights platform transforming compliance barriers into competitive advantage, today announced the appointment of Timothy Nobles as the company's Chief Product Officer. Nobles, who previously served as Integral's Chief Commercial Officer, will now lead product innovation to help enterprises extract unique, previously unavailable insights from their most valuable regulated data assets.
Nobles brings more than two decades of experience in data and analytics to this position, having worked in early and growth-stage companies across the Original Equipment Manufacturer (OEM) automotive, FinTech and healthcare industries. Before joining Integral, Nobles served as Chief Product Officer at Trilliant Health, where he focused on expansive predictive analytics for the health economy. He also formerly served as Head of Product at Embold Health, working on objective provider quality measurements to aid self-insured employers in guiding their employees toward high-value healthcare providers based on their specific care needs.
'Timothy's leadership comes at a crucial time when the industry is drowning in data but starving for insights,' said Shubh Sinha, CEO of Integral. 'His deep understanding of our customers' challenges will help us further refine our end-to-end platform to meet their most pressing needs. While companies struggle with slow, manual compliance processes that block innovation, we're focused on helping them rapidly access compliant data and extract unique insights that weren't previously possible. Timothy's product vision will accelerate our mission of turning what others see as compliance overhead into a strategic competitive advantage for the enterprises we serve.'
To learn more about Integral, visit www.useintegral.com
About Integral
Integral is the only end-to-end regulated insights platform transforming compliance barriers into competitive advantage. We help data-driven enterprises extract bespoke, actionable insights from regulated data that aren't available anywhere else, while protecting against re-identification risk. By replacing fragmented tools and consulting delays with a single platform that continuously evaluates, transforms, and activates regulated data, Integral enables organizations to unlock previously inaccessible data streams and turn regulatory requirements into competitive advantages. www.useintegral.com
View source version on businesswire.com:https://www.businesswire.com/news/home/20250603357918/en/
CONTACT: Media Contact
Innsena for Integral
[email protected]
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: RESEARCH TECHNOLOGY CLINICAL TRIALS PROFESSIONAL SERVICES SOFTWARE DATA ANALYTICS HEALTH DATA MANAGEMENT SCIENCE OTHER SCIENCE
SOURCE: Integral
Copyright Business Wire 2025.
PUB: 06/03/2025 08:05 AM/DISC: 06/03/2025 08:03 AM
http://www.businesswire.com/news/home/20250603357918/en
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
22 minutes ago
- Associated Press
Denmark Data Center Portfolio Report 2025: Detailed Analysis of 27 Existing and 5 Upcoming Data Center Facilities
DUBLIN--(BUSINESS WIRE)--Jun 6, 2025-- The 'Denmark Existing & Upcoming Data Center Portfolio' database has been added to offering. Denmark currently has over 25 active data centers with around 100 MW of total IT power. The upcoming capacity is expected to reach 400 MW - more than four times the existing capacity. atNorth and Prime Data Centers are leading upcoming developments with large-scale projects. Digital Realty and STACK Infrastructure are among the top existing operators with nearly 70 MW of combined capacity. Around 60% of the current rack capacity is centered in Copenhagen. Aarhus and Skanderborg are gaining attention as emerging data center hubs. Most of the upcoming facilities are planned in and around Copenhagen, reinforcing its position as the country's core data center market. Key Market Highlights This database (Excel) product covers the Denmark data center market portfolio analysis, which will provide the following information on the colocation data centers: Existing Data Centers (27 Facilities) Upcoming Data Centers (5 Facilities) Target Audience Key Topics Covered: 1. About the Database 2. Scope & Assumptions 3. Definitions 4. Snapshot: Existing & Upcoming Data Center Facility 5. Existing Data Center Database 6. Upcoming Data Center Facility 7. Existing vs. Upcoming Capacity (Infographics) 8. Colocation Pricing The major operators/investors covered in this Denmark Data Center Colocation Market Database include: For more information about this database visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: DENMARK EUROPE INDUSTRY KEYWORD: TECHNOLOGY HARDWARE DATA MANAGEMENT SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 06/06/2025 08:04 AM/DISC: 06/06/2025 08:02 AM
Associated Press
22 minutes ago
- Associated Press
Italy Existing & Upcoming Data Center Portfolio Analysis Report 2025: Eni & G42 Drive Over 50% of Italy's Data Center Growth in Upcoming Market
DUBLIN--(BUSINESS WIRE)--Jun 6, 2025-- The 'Italy Existing & Upcoming Data Center Portfolio' database has been added to offering. Milan dominates the upcoming data center market in Italy. Italy is seen as an ideal location for data centers with its geographical benefits. Major cities like London, Amsterdam, Dublin, and facing network saturation, Italy stands out as a new hub for data infrastructure. The upcoming IT power capacity is around 2 GW, nearly 2x the current capacity. Eni & G42 alone account for over 50% of the upcoming power and rack supply. CloudHQ, STACK Infrastructure, and CyrusOne are key new entrants driving future growth. DATA4, Telecom Italia (TIM), and Aruba are among the leading existing operators. Key Market Highlights This database (Excel) product covers the Italy data center market portfolio analysis, which will provide the following information on the colocation data centers: Existing Data Centers (69 Facilities) Upcoming Data Centers (17 Facilities) Target Audience Key Topics Covered: 1. About the Database 2. Scope & Assumptions 3. Definitions 4. Snapshot: Existing & Upcoming Data Center Facility 5. Existing Data Center Database 6. Upcoming Data Center Facility 7. Existing vs. Upcoming Capacity (Infographics) 8. Colocation Pricing The major operators/investors covered in this Italy Data Center Colocation Market Database include: For more information about this database visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: ITALY EUROPE INDUSTRY KEYWORD: TECHNOLOGY INTERNET HARDWARE DATA MANAGEMENT SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 06/06/2025 08:01 AM/DISC: 06/06/2025 08:01 AM
Business Wire
33 minutes ago
- Business Wire
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors
MINNEAPOLIS--(BUSINESS WIRE)-- HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. 'Our vision is for the Edison System to become a foundational, non-invasive solution across a wide range of clinical applications,' said Mike Blue, President and CEO, HistoSonics. The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #HOPE4KIDNEY trial is expected to support a future submission for regulatory clearance to expand the use of histotripsy to treat kidney tissue/tumors. The Edison System is the first and only platform to use histotripsy, a non-thermal, non-invasive focused ultrasound technology, to mechanically liquefy tumors without surgery, radiation, or systemic therapies. Unlike invasive surgical approaches, histotripsy does not require incisions and enables real-time imaging and treatment monitoring, allowing physicians to target and control tissue destruction while sparing surrounding structures. 'Our vision is for the Edison System to become a foundational, non-invasive solution across a wide range of clinical applications,' said Mike Blue, President and CEO, HistoSonics. 'Completing enrollment in our pivotal kidney tumor trial represents a significant milestone toward that goal and reinforces our confidence in expanding histotripsy into additional tumor types and indications. This achievement reflects the dedication of our team and clinical partners and brings us closer to transforming the treatment of solid tumors without the need for surgery.' Dr. William C. Huang, MD FACS, Professor and Vice Chair of Urology at the NYU Grossman School of Medicine serves as a principal investigator at the NYU Langone Medical Center, the top enrolling site in the trial. Dr. Huang commented, 'Histotripsy offers a novel, completely non-invasive treatment paradigm for kidney tumors that precisely images and treats tumors while preserving surrounding critical structures thereby minimizing the morbidity associated with traditional surgical and thermal ablative techniques.' Dr. Michael McDonald, Assistant Professor of Urology at the University of Central Florida College of Medicine and Urologic Surgeon at AdventHealth at Celebration Florida, serves as a principal investigator for one of the participating sites in the trial. Dr. McDonald commented, 'HistoSonics represents a paradigm shift proving that the most profound treatments for both benign and malignant diseases need not be the most invasive. The ability to precisely target and destroy tumors without scalpel or scar is the next step in the evolution of non-surgical intervention.' The Edison System has not been evaluated for the treatment of any specific disease, including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumour progression, 5-year survival or overall survival). United States Intended Use Statement: The Edison System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by physicians who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions, and a summary of clinical trial results, including reported adverse events. About HistoSonics HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, and others. HistoSonics has offices in Ann Arbor, Michigan and Minneapolis, MN. For more information on the Edison Histotripsy System please visit: For patient-related information please visit:
